Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This locus encodes a readthrough RNA transcript that merges the SLX1A (structure-specific endonuclease subunit A) and SULT1A3 (sulfotransferase family 1A member 3) genes on chromosome 16[1][2][5]. The transcript is likely subject to nonsense-mediated mRNA decay (NMD) and does not produce a functional protein product[1][2][5]. Therefore, SLX1A-SULT1A3 itself is not a protein or drug target, though SULT1A3 as a separate gene encodes a legitimate drug-metabolizing enzyme.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SLX1A-SULT1A3 readthrough (non-protein coding) (SLX1A-SULT1A3).